SIBO vs. H. Pylori: What’s the Difference?

SIBO and H. pylori are two distinct gut conditions that affect different parts of the digestive tract, involve different organisms, and require different treatments, yet they produce symptoms similar enough to confuse patients and clinicians alike. H. pylori is a specific bacterium that colonizes the stomach lining, while SIBO is a condition in which bacteria that normally belong in the colon proliferate in the small intestine. The overlap in bloating, nausea, and abdominal discomfort makes it easy to mistake one for the other, and the two can even coexist in the same person, which complicates things further.

Where Each One Lives and What It Does

The most fundamental difference is location. H. pylori is a spiral-shaped bacterium with whip-like flagella that allow it to burrow into the mucus layer of the stomach. It thrives in the stomach’s harsh acidic environment and can persist there for decades. Colonization is asymptomatic in roughly nine out of ten people, but in the remainder it drives gastritis, stomach ulcers, and is a recognized risk factor for gastric cancer.¹ It is not a condition defined by bacterial excess; it is a single species of pathogen that shouldn’t be there at all.

SIBO, by contrast, is not caused by one specific organism. It is defined by an abnormal proliferation of bacteria, typically species that belong in the colon, taking up residence in the small intestine.² The small intestine is supposed to have relatively few bacteria compared to the colon. When that balance breaks down, the misplaced bacteria ferment food in the wrong place, producing gas and other byproducts that cause the hallmark symptoms of bloating, cramping, and diarrhea. So while H. pylori is one organism in one organ, SIBO is many organisms in the wrong organ.

How Symptoms Overlap and Where They Diverge

Both conditions can cause bloating, nausea, and upper abdominal discomfort, which is why people frequently wonder whether they have one, the other, or both.³ But the patterns tend to differ. H. pylori symptoms, when they appear at all, lean toward burning or gnawing stomach pain that worsens on an empty stomach, loss of appetite, and sometimes dark stools if an ulcer is bleeding. The pain is often centered high in the abdomen, right below the sternum.

SIBO symptoms tend to revolve more around the consequences of bacterial fermentation: excessive gas, abdominal distension that worsens after meals (especially carbohydrate-heavy ones), diarrhea or alternating bowel habits, and a general feeling of fullness even after eating small amounts. Over time, SIBO can also cause fatty, foul-smelling stools if fat absorption is compromised. The key practical difference is timing and triggers. SIBO discomfort typically flares after eating, particularly certain foods, while H. pylori pain may actually improve briefly with food before returning.

That said, plenty of patients present with vague, overlapping complaints that fit either diagnosis. One study in the World Journal of Clinical Cases noted that the clinical symptoms of these two conditions “may also overlap with one and another” and that no clear clinical guidelines exist for testing for SIBO specifically in patients with H. pylori infection.³ This gap means that if your doctor only tests for one, the other could easily be missed.

How Each Is Diagnosed

Testing for H. pylori is relatively straightforward. The most common non-invasive methods are a urea breath test, a stool antigen test, and blood antibody testing, though antibody tests can stay positive long after the infection clears, so they are less useful for confirming active infection. During an upper endoscopy, a biopsy can confirm H. pylori directly. These tests are well-standardized and widely available.

SIBO testing is murkier. The most common approach is a breath test using either lactulose or glucose as a substrate. You drink the sugar solution, and then breathe into collection tubes at intervals. Bacteria fermenting the substrate in the small intestine produce hydrogen or methane gas, which is absorbed into the bloodstream and exhaled. A rise in these gases above certain thresholds at specific time points is interpreted as positive. But breath testing for SIBO has inherent limitations, and results need to be interpreted alongside the clinical picture and other influencing factors.⁴ Transit time varies between people, prep instructions matter, and the cutoff values that define a positive result aren’t universally agreed upon. The gold standard for SIBO diagnosis is actually an aspirate of small bowel fluid during endoscopy and culturing it, but this is invasive, expensive, and rarely done in routine practice.

One important distinction for patients: the urea breath test for H. pylori and the hydrogen/methane breath test for SIBO are completely different tests despite both involving breathing into a tube. They measure different gases produced by different organisms in different parts of the gut. Confusing the two is surprisingly common.

The Hydrogen-Methane Distinction in SIBO

SIBO itself is not a single entity. The type of gas that shows up on a breath test matters because it affects symptoms and treatment. Hydrogen-dominant SIBO tends to be associated more with diarrhea, while methane-dominant overgrowth, now often called intestinal methanogen overgrowth (IMO), is more closely linked to constipation. IMO involves an increase in methane-producing archaea, specifically Methanobrevibacter smithii, rather than the typical colon bacteria that define hydrogen-dominant SIBO.² This is a meaningful distinction because methanogens are not bacteria; they are a completely separate domain of life called archaea. Antibiotics that work against bacteria don’t always work against them.

H. pylori has no such subtyping issue for the patient. It is one species, and though different strains carry different virulence factors (some with more aggressive proteins that raise ulcer and cancer risk), the treatment approach doesn’t change based on strain in most clinical settings. The takeaway: if you have SIBO, your doctor may want to know which type of gas you’re producing. If you have H. pylori, the diagnosis is more binary.

How H. Pylori Can Actually Promote SIBO

These two conditions are not entirely independent. A growing body of evidence suggests that H. pylori infection may increase the risk of developing SIBO. A systematic review and meta-analysis published in BMC Microbiology found that H. pylori infection was associated with roughly 80% higher odds of having SIBO. The association was particularly strong in younger patients, where the odds roughly tripled, but it was not statistically significant in older patients.⁵

A separate study examining 102 patients directly compared SIBO rates between those with and without H. pylori. Among H. pylori-positive patients, about half tested positive for SIBO, compared to roughly a quarter of those without H. pylori. The same pattern held for methane-dominant IMO.⁶

The likely mechanism involves stomach acid. H. pylori causes chronic inflammation of the stomach lining, and over time this can reduce acid production. Stomach acid is one of the body’s primary defenses against bacteria passing from the mouth and esophagus into the small intestine. When that acid barrier weakens, more bacteria survive the trip and can colonize the small bowel. This is the same mechanism behind the PPI connection discussed below.

The Proton Pump Inhibitor Problem

This is where things get clinically tricky. H. pylori treatment typically includes a proton pump inhibitor (PPI) to reduce stomach acid, paired with antibiotics. PPIs are also prescribed on their own for acid reflux and ulcer symptoms. But the very same acid suppression that helps heal H. pylori damage can open the door to SIBO.

A 2025 systematic review and meta-analysis found that PPI-treated patients had a SIBO prevalence of about 37%, compared to roughly 20% in controls. PPI use was associated with about double the odds of SIBO, and the risk climbed with duration. Each additional month of PPI therapy was associated with a measurable increase in SIBO prevalence. Patients on PPIs for more than six months had over four times the odds of developing SIBO compared to non-users.⁷

This creates a paradox for patients being treated for H. pylori. The PPI you need to clear the infection and heal the stomach lining may simultaneously be raising your risk of bacterial overgrowth downstream. For short courses, like the typical 10-14 day H. pylori eradication regimen, the risk is likely modest. The real concern is when patients remain on PPIs long-term after treatment ends, whether for ongoing reflux or simply because nobody revisited whether the prescription was still necessary. If you’ve been on a PPI for months and develop new bloating or diarrhea, SIBO is worth considering.

How Treatment Differs

H. pylori eradication follows well-established protocols. The standard approach is triple or quadruple therapy: a PPI combined with two or three antibiotics taken for 10 to 14 days. One common regimen uses a PPI with amoxicillin and metronidazole.⁸ Confirmation of eradication is typically done at least four weeks later with a urea breath test or stool antigen test. Treatment success rates have been declining in some regions due to antibiotic resistance, but the framework is clear and guideline-driven.

SIBO treatment is less standardized. The most commonly used antibiotic is rifaximin, which stays mostly in the gut and has fewer systemic side effects. For methane-dominant overgrowth, rifaximin is often combined with another antibiotic because methanogens resist single-agent therapy. Some clinicians use herbal antimicrobial protocols as an alternative, though the evidence base for these is thinner. Importantly, SIBO has a frustratingly high recurrence rate. Unlike H. pylori, where successful eradication usually means the infection is gone for good, SIBO tends to come back unless the underlying cause is addressed. If the problem is slow gut motility, adhesions from surgery, or chronic PPI use, the bacteria will simply repopulate once antibiotics stop.

The study that tested amoxicillin plus rifaximin in patients with both conditions simultaneously found that the combination could address both at once, which highlights the overlap in management when someone has both.⁸ But this is far from standard practice; no clinical guidelines currently exist for how to handle the dual diagnosis.

The Nutritional Fallout

Both conditions can quietly cause nutritional deficiencies, though through different mechanisms. H. pylori-induced gastritis damages the stomach lining and can interfere with the production of intrinsic factor, a protein the stomach makes specifically to help absorb vitamin B12. The inflammation disrupts the normal breakdown and binding of B12 from food, and in some patients, eradicating the infection reverses the deficiency, which strongly suggests H. pylori was the cause.⁹ Iron deficiency is another common consequence of H. pylori gastritis, since acid is needed to convert dietary iron into a form the body can absorb.

SIBO causes malabsorption through a different route. The excess bacteria in the small intestine consume nutrients before you can absorb them, particularly B12, and they can damage the intestinal lining, impairing fat absorption. This leads to deficiencies in fat-soluble vitamins (A, D, E, K) and can cause fatty stools. Prolonged SIBO may also impair iron and protein absorption. The practical implication is that if you’ve been diagnosed with either condition and your doctor hasn’t checked your B12, iron, and vitamin D levels, it’s worth asking.

Diet’s Role in Each Condition

Diet plays a much larger role in managing SIBO than H. pylori. For H. pylori, there is no specific dietary therapy; the infection requires antibiotics. Some people find that spicy or acidic foods worsen their symptoms during active gastritis, but avoiding those foods does not treat the infection itself.

For SIBO, dietary management is considered an important part of both treatment and relapse prevention. A significant portion of patients diagnosed with irritable bowel syndrome also have SIBO, and dietary strategies like reducing fermentable carbohydrates can help control symptoms.¹⁰ Low-FODMAP diets, elemental diets (liquid formulas that are fully absorbed in the upper gut, starving bacteria of fuel), and other restrictive approaches are commonly used alongside or after antibiotic treatment. The goal is to deprive the misplaced bacteria of their food source while keeping you nourished. These diets can be effective but are difficult to maintain long-term and carry their own risk of nutritional gaps if not properly supervised.

What Happens to Your Gut After Eradication

Clearing H. pylori doesn’t immediately return everything to normal downstream. The antibiotics used in eradication therapy temporarily disrupt the broader gut microbiome. A systematic review of 24 studies found that gut bacterial diversity dropped in the weeks after H. pylori treatment, with certain beneficial bacteria like Lactobacillus declining while potentially problematic groups increased. However, the microbiome generally restored itself to its baseline composition over the following one to two years.¹¹

This temporary disruption is worth knowing about because it means you may experience new digestive symptoms for weeks or even months after finishing H. pylori treatment. Some patients report that their gut “felt worse” before it got better. This is also a window where SIBO could theoretically gain a foothold, since the normal microbial ecosystem has been shaken up. If bloating or diarrhea persist well beyond the treatment course, it’s reasonable to ask whether SIBO might have developed in the aftermath.

SIBO recurrence after treatment is a separate and well-recognized problem. Because SIBO is often a downstream consequence of something else (slow motility, anatomical changes, or ongoing acid suppression), treating the bacteria without addressing the root cause means the small intestine will often become recolonized. Some patients go through multiple rounds of antibiotic therapy over years. Prokinetic agents, which stimulate gut motility and help sweep bacteria out of the small intestine, are sometimes used between antibiotic courses to reduce recurrence.

Beyond the Gut

H. pylori’s effects are not limited to the stomach. Research has linked the infection to several autoimmune conditions, including rheumatoid arthritis, psoriasis, and lupus, through mechanisms involving chronic inflammation and molecular mimicry, where the immune system mistakes the body’s own tissues for parts of the bacterium.¹² The clinical significance of these associations is still debated, but it underscores that H. pylori is not just a stomach problem. It is a chronic infection with systemic inflammatory effects.

SIBO’s extraintestinal effects tend to be driven more by malabsorption and the downstream consequences of nutrient deficiency. Chronic B12 deficiency can cause neurological symptoms like numbness and cognitive changes. Vitamin D deficiency affects bone density. Fat malabsorption can lead to easy bruising from vitamin K depletion. These effects are real but are consequences of poor nutrient uptake rather than the direct action of the bacteria themselves, which marks a meaningful difference from H. pylori’s more direct immunological involvement throughout the body.

When You Might Have Both

Given the evidence that H. pylori raises SIBO risk, some patients will have both simultaneously. The challenge is that no clinical guidelines currently address this dual diagnosis.³ In practice, this means your gastroenterologist might treat H. pylori first and then reassess your symptoms, only testing for SIBO if bloating and diarrhea persist. Or, if both are diagnosed up front, a regimen that includes rifaximin alongside the standard H. pylori antibiotics may address both at once.

If you’ve been treated for H. pylori and still feel lousy weeks later, don’t assume the treatment failed. It may have worked perfectly against H. pylori while leaving a coexisting SIBO untouched, or the treatment itself may have contributed to bacterial shifts that worsened an existing overgrowth. The younger you are, the stronger the statistical association between H. pylori and concurrent SIBO appears to be, based on the subgroup analysis showing the connection was most robust in patients under 48.⁵ Bringing this up with your doctor is reasonable if your post-treatment symptoms don’t match what’s expected.